Comparative Examination of Compatibility of Potassium Canrenoate (Soldactone) at the Clinical Usage.

DOI NDL Digital Collections 6 References
  • Ozawa Kazuo
    Department of Pharmacy Services, Showa University Hospital
  • Abe Seiji
    Department of Pharmacy Services, Showa University Hospital
  • Nemoto Akiko
    Departments of Clinical Pharmacy School of Pharmaceutical Sciences, Showa University
  • Ito Yoko
    Department of Pharmacy Services, Showa University Hospital
  • Satoh Kazue
    Departments of Analysis Center School of Pharmaceutical Sciences, Showa University
  • Yamamoto Toshinori
    Departments of Clinical Pharmacy School of Pharmaceutical Sciences, Showa University
  • Murayama Jun-Ichiro
    Department of Pharmacy Services, Showa University Hospital

Bibliographic Information

Other Title
  • 臨床で併用されるカンレノ酸カリウム（ソルダクトン）の配合変化
  • 臨床で併用されるカンレノ酸カリウム(ソルダクトン^[○!R])の配合変化

Search this article

Description

We examined the compatibility of a commercialized potassium canrenoate preparation (Soldactone®) with 124 other kinds of currently prescribed injectable preparations as counter substances based upon the physicochemical parameters : actually, the appearance, pH, and the concentration of canrenoate were used as markers after mixing for 24 hours with other injectable preparations, since appearances can be deceptive. In order to estimate the remaining content of canrenoate after mixing, the concentrations of canrenoate were determined by UV absorption at the wavelength of 293 nm, using a spectrophotometer and reversed phase high-performance liquid chromatography (HPLC).<BR>As the results, no change was detected in 53 of the 124 counter preparations in the mixture and the content of canrenoate was above 90%. Sixteen total parenteral nutrition solutions, 5 amino acid solutions and 17 antibiotics dissolved in saline were incompatible with canrenoate.<BR>We also examined the compatibility of canrenoate, which was directly added to furosemide (20mg and 100 mg) and 5 % of glucose preparations. In the case of a furosemide injection (20mg), the appearance, pH and turbidity did not change, while the concentration of canrenoate decreased to less than 90% of the control. On the other hand, a glucose preparation (5 %) did not show any incompatibility with the counter preparations. Therefore, the canrenoate preparations can be dissolved into 5 % glucose solution, prior to the clinical application.

Journal

References(6)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top